MMP11 and posterior cortical atrophy: We have additionally validated MMP11 as a marker of metastases using plasma samples (n = 43) from patients with primary or metastatic PCa (hormone-sensitive PCa or CRPC) treated with radical prostatectomy (primary PCa) or taxane-based chemotherapy, docetaxel or cabazitaxel (metastatic PCa) (Table 2).